Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01813929 · ClinicalTrials.gov registry record · Phase 4

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

A Phase 4 study, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 4
Development phase
23
Enrollment target

NCT01813929 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 23 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01813929, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 4
Development phase
23 participants
Enrollment target

Study Summary

Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on insulin sensitivity, vascular function and compliance, and mitochondrial function in T1D. The long term goal is to identify novel non-glycemic approaches to managing cardiovascular disease risk in T1D. The results of this study may validate a novel approach to T1D treatment that could significantly improve current management of cardiovascular disease risk in this high risk population.

Interventions

  • DRUG Placebo
  • DRUG Metformin

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2011-06
Est. Completion 2017-03-24
Phase Phase 4

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT01813929

The ClinicalTrials.gov registry entry for NCT01813929 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01813929 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01813929 about?

NCT01813929 is a clinical study titled "Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes". Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on insulin sensitivity, vascular function and compliance, and mitochondrial function in T1D. The long term goal is to...

What is the current status of trial NCT01813929?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2011-06. Estimated completion is 2017-03-24.

What interventions are being tested in trial NCT01813929?

The interventions under investigation include: Placebo (DRUG), Metformin (DRUG).

Who is sponsoring clinical trial NCT01813929?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.